BR112023022041A2 - Anticorpos anti-tslp modificados - Google Patents

Anticorpos anti-tslp modificados

Info

Publication number
BR112023022041A2
BR112023022041A2 BR112023022041A BR112023022041A BR112023022041A2 BR 112023022041 A2 BR112023022041 A2 BR 112023022041A2 BR 112023022041 A BR112023022041 A BR 112023022041A BR 112023022041 A BR112023022041 A BR 112023022041A BR 112023022041 A2 BR112023022041 A2 BR 112023022041A2
Authority
BR
Brazil
Prior art keywords
modified anti
tslp antibodies
tslp
tezepelumab
antibodies
Prior art date
Application number
BR112023022041A
Other languages
English (en)
Inventor
Hao Zhang
Liuqing Shi
Pavel Bondarenko
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BR112023022041A2 publication Critical patent/BR112023022041A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

anticorpos anti-tslp modificados. o presente pedido se relaciona, em geral, com composições ou variantes do anticorpo anti-tslp tezepelumab tendo estabilidade aumentada em comparação com o tezepelumab quando armazenado ao longo de longos períodos de tempo.
BR112023022041A 2021-04-23 2022-04-22 Anticorpos anti-tslp modificados BR112023022041A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163178915P 2021-04-23 2021-04-23
PCT/US2022/025999 WO2022226342A2 (en) 2021-04-23 2022-04-22 Modified anti-tslp antibodies

Publications (1)

Publication Number Publication Date
BR112023022041A2 true BR112023022041A2 (pt) 2023-12-26

Family

ID=81597885

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023022041A BR112023022041A2 (pt) 2021-04-23 2022-04-22 Anticorpos anti-tslp modificados

Country Status (12)

Country Link
EP (1) EP4326762A2 (pt)
JP (1) JP2024516595A (pt)
KR (1) KR20230175245A (pt)
CN (1) CN117177992A (pt)
AR (1) AR125404A1 (pt)
AU (1) AU2022262006A1 (pt)
BR (1) BR112023022041A2 (pt)
CA (1) CA3216700A1 (pt)
CL (1) CL2023003124A1 (pt)
IL (1) IL307439A (pt)
TW (1) TW202304980A (pt)
WO (1) WO2022226342A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4375659A1 (en) * 2022-11-28 2024-05-29 Takeda Vaccines, Inc. A method for the quantitative determination of human serum albumin monomer in virus-containing pharmaceutical compositions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
WO2006075668A1 (ja) * 2005-01-12 2006-07-20 Kirin Beer Kabushiki Kaisha 安定化されたヒトIgG2およびIgG3抗体
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
JP5334319B2 (ja) * 2007-09-26 2013-11-06 中外製薬株式会社 Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
WO2012007495A1 (en) 2010-07-15 2012-01-19 F. Hoffmann-La Roche Ag Antibodies specifically binding to human tslpr and methods of use
AT510032B1 (de) 2010-11-30 2012-01-15 Steiner Erwin Ing Montageeinrichtung für fassadenelemente
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
WO2014031718A1 (en) * 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
CN107428828A (zh) * 2015-03-11 2017-12-01 葛兰素史密斯克莱知识产权发展有限公司 Tslp结合蛋白
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
MX2019014615A (es) 2017-06-08 2020-02-07 Amgen Inc Dispositivo de administracion de farmacos accionado por par de torsion.
EP3662287B1 (en) * 2017-08-01 2024-02-28 Amgen Inc. Systems and methods for real time preparation of a polypeptide sample for anaylsis with mass spectrometry
CN111225696B (zh) 2017-11-10 2023-07-18 安进公司 用于药物递送装置的柱塞
CA3093699A1 (en) 2018-03-13 2019-09-19 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
EP3866889A1 (en) 2018-10-15 2021-08-25 Amgen Inc. Platform assembly process for drug delivery device
EA202191037A1 (ru) 2018-10-15 2021-08-05 Эмджен Инк. Устройство доставки лекарственного средства, имеющее демпферный механизм
MX2021014733A (es) 2019-06-05 2022-04-06 Amgen Inc Metodos de identificacion de atributos de proteinas terapeuticas.

Also Published As

Publication number Publication date
CN117177992A (zh) 2023-12-05
TW202304980A (zh) 2023-02-01
JP2024516595A (ja) 2024-04-16
CA3216700A1 (en) 2022-10-27
IL307439A (en) 2023-12-01
CL2023003124A1 (es) 2024-04-26
AR125404A1 (es) 2023-07-12
WO2022226342A2 (en) 2022-10-27
EP4326762A2 (en) 2024-02-28
WO2022226342A3 (en) 2022-12-01
AU2022262006A1 (en) 2023-10-19
KR20230175245A (ko) 2023-12-29

Similar Documents

Publication Publication Date Title
EA202190435A1 (ru) Конструкции на основе антител для связывания cldn18.2 и cd3
NO20064239L (no) Anti-AB-antistoff
RS54405B1 (en) HUMANIZED ANTI-FACTOR ANTIBODIES AND THEIR APPLICATIONS
RS52769B (sr) Kompozicije i postupci za povećanje mineralizacije kostiju
EA201991769A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ С НИЗКИМ ПОКАЗАТЕЛЕМ pH, СОДЕРЖАЩАЯ КОНСТРУКЦИИ НА ОСНОВЕ АНТИТЕЛА, ОСУЩЕСТВЛЯЮЩИЕ РЕКРУТИНГ Т-КЛЕТОК
RS53984B1 (en) IP-10 ANTIBODIES AND THEIR USES
PE20090359A1 (es) Polipeptidos, dominios variables de anticuerpos y antagonistas
DE602004028651D1 (de) Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper
BRPI0811198B8 (pt) fosfatase alcalina direcionada a osso, kits e métodos de seu uso
DE60113381D1 (de) Automatisierung im proteinentwurf durch proteinbibliotheken
EA201890320A1 (ru) Молекулы антител, которые связывают cd79
DE60327205D1 (de) Therapeutische antiköper mit reduzierten nebenwirkungen
WO2022031884A3 (en) Il2rg binding molecules and methods of use
MX344040B (es) Anticuerpos mejorados de la clase inmonoglubina g4 (igg4).
MX2023001491A (es) Moleculas de union a gp130 y metodos de uso.
BR112022018949A2 (pt) Anticorpos monoclonais humanos para síndrome respiratória aguda grave coronavírus 2 (sars-cov-2)
BR112022011570A2 (pt) Anticorpos anti-mertk e métodos de uso dos mesmos
BR112023022041A2 (pt) Anticorpos anti-tslp modificados
MX2022006893A (es) Conjugado anticuerpo-farmaco anti-claudina y uso farmaceutico del mismo.
WO2022032006A3 (en) Il2rb binding molecules and methods of use
BRPI0507019A (pt) composição, uso de anticorpo, anticorpo, uso de msrv/herv-w env-su
AU2021269176A8 (en) Single domain antibodies binding to SARS-CoV-2 spike protein
WO2022031885A3 (en) Il10ra binding molecules and methods of use
MX2022010621A (es) Anticuerpos anti-cd19 humano.
MX2021011995A (es) Composicion farmaceutica acuosa de anticuerpo anti-il17a y su uso.